Palmaz-Schatz stent

Palmaz-Schatz stent

Cardiology A balloon-expandable coronary stent delivered via balloon angioplasty, which remains in the expanded artery to maintain patency and prevent restenosis. See Percutaneous transluminal angiography.
Mentioned in ?
References in periodicals archive ?
Bard, the Crown(TM) stent, an improvement to the original Palmaz-Schatz stent, for Johnson & Johnson, the iBOT(TM) mobility device, and the Segway Human Transporter.
Comparison of immediate and intermediate-term results of intravascular ultrasound versus angiography-guided Palmaz-Schatz stent implantation in matched lesions.
Soon afterward, Johnson & Johnson became a market leader with its Palmaz-Schatz stent, which the FDA approved in 1994.
Romano was a principal in EGP, a partnership that held the licensing rights to the Palmaz-Schatz Stent cardiovascular device.
a leading interventional cardiologist that pioneered coronary stent technology as co-developer of the Palmaz-Schatz Stent, will perform a live-case procedure at Scripps Clinic in La Jolla, California, using Bioheart's innovative MyoCell(R) Clinical Cell Therapy for treating patients with congestive heart failure.
Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials.
a publicly traded technology company, and a principal in EGP, a partnership that held the licensing rights to the Palmaz-Schatz Stent cardiovascular device that was purchased by Johnson & Johnson in 1998.
Schatz is an early pioneer of coronary stent technology and is best known for the co-development of the first successful coronary stent, the Palmaz-Schatz stent.
J&J attributes revenue and earnings growth from new products introduced over the past several years as exemplified by the PALMAZ-SCHATZ stent for coronary artery disease.
This is the first trial that demonstrates a new stent with long-term clinical results equal to or better than the original PALMAZ-SCHATZ Stent," said James P.
It is believed to be the first clinical trial to utilize the Palmaz-Schatz stent from Johnson & Johnson Interventional Systems (JJIS) as the concurrent control.
The SMART trial evaluates the treatment of untreated and previously treated (restenotic) lesions in native coronary arteries, utilizing Johnson & Johnson's Palmaz-Schatz stent as a concurrent control.